EBS Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -148.33%. Emergent BioSolutions's return on equity of -35.42% beat Editas Medicine's return on equity of -100%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 145.9%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 143.51%. Given that Emergent BioSolutions has higher upside potential than Editas Medicine, analysts believe Emergent BioSolutions is more attractive than Editas Medicine.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.479%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Editas Medicine quarterly revenues of $30.6M. Emergent BioSolutions's net income of -$31.3M is higher than Editas Medicine's net income of -$45.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.29x versus 3.92x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -1816.75%. Emergent BioSolutions's return on equity of -35.42% beat Ocugen's return on equity of -171.04%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 145.9%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 838.54%. Given that Ocugen has higher upside potential than Emergent BioSolutions, analysts believe Ocugen is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocugen quarterly revenues of $764K. Emergent BioSolutions's net income of -$31.3M is lower than Ocugen's net income of -$13.9M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.29x versus 48.06x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -283.27%. Emergent BioSolutions's return on equity of -35.42% beat Ocular Therapeutix's return on equity of -62.66%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 145.9%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 126.98%. Given that Emergent BioSolutions has higher upside potential than Ocular Therapeutix, analysts believe Emergent BioSolutions is more attractive than Ocular Therapeutix.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Emergent BioSolutions's net income of -$31.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.29x versus 19.15x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 21.57%. Emergent BioSolutions's return on equity of -35.42% beat TG Therapeutics's return on equity of 12.81%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 145.9%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 4.04%. Given that Emergent BioSolutions has higher upside potential than TG Therapeutics, analysts believe Emergent BioSolutions is more attractive than TG Therapeutics.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than TG Therapeutics quarterly revenues of $108.2M. Emergent BioSolutions's net income of -$31.3M is lower than TG Therapeutics's net income of $23.3M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 295.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.29x versus 19.68x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.